Skip to content
WorldBrand.AI

Adakveo

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2019

    FDA approves Adakveo for sickle cell disease pain crises

    The FDA approved crizanlizumab (Adakveo, Novartis) to reduce the frequency of pain crises among people with sickle cell disease; the article states it is indicated for patients aged 16 or older.

    Source